Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 3:09 AM
Ignite Modification Date:
2025-12-25 @ 3:09 AM
NCT ID:
NCT05520905
Eligibility Criteria:
Inclusion Criteria:
* HIV negative
* Eligible for PrEP using emtricitabine (F)/tenofovir alafenamide (TAF) (F/TAF) (brand name Descovy) based on current CDC guidance
* assigned male at birth
* has had male sex partners in the past 6 months (and not in a monogamous partnership with a recently tested, HIV-negative man) and
* either any sex without a condom in the past 6 months or
* a bacterial sexually transmitted infection
* Consents to TelePrEPvisits
* Willing to use current insurance coverage for clinic and laboratory services OR willing to be assisted to obtain insurance coverage OR eligible for other coverage such as Title X funds or charity care
Exclusion Criteria:
* HIV-infection or concern for acute HIV infection until ruled out
* Pregnancy
* Persons at risk through receptive vaginal sex including cisgender women and transgender men (persons assigned female sex at birth)
* Persons with only injection drug indications for PrEP without sexual risk indications outlined in inclusion criteria
Healthy Volunteers:
True
Sex:
MALE
Minimum Age:
14 Years
Maximum Age:
24 Years
Study:
NCT05520905
Study Brief:
Protocol Section:
NCT05520905